US 12,234,207 B2
Halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and use thereof
Ki Duk Park, Seoul (KR); Ae Nim Pae, Seoul (KR); Sang Min Lim, Seoul (KR); Jong Hyun Park, Seoul (KR); Ji Won Choi, Seoul (KR); Siwon Kim, Seoul (KR); Hyeon Jeong Kim, Seoul (KR); and Seul Ki Yeon, Seoul (KR)
Assigned to CUREVERSE INCORPORATED, Seoul (KR)
Appl. No. 17/268,958
Filed by Cureverse Incorporated, Seoul (KR)
PCT Filed Aug. 19, 2019, PCT No. PCT/KR2019/010513
§ 371(c)(1), (2) Date Mar. 16, 2021,
PCT Pub. No. WO2020/036474, PCT Pub. Date Feb. 20, 2020.
Claims priority of application No. 10-2018-0096167 (KR), filed on Aug. 17, 2018.
Prior Publication US 2021/0317083 A1, Oct. 14, 2021
Int. Cl. C07D 213/52 (2006.01); C07F 9/40 (2006.01)
CPC C07D 213/52 (2013.01) [C07F 9/4071 (2013.01)] 20 Claims
 
1. A compound represented by Chemical Formula 1 below or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein, in the Chemical Formula 1,

OG Complex Work Unit Chemistry
R1 is a halogen,
R2 is hydrogen or C1-4 alkyl,
n is an integer of 1 to 5, and
X is a halogen.